Identification of an Exosome-relevant SNHG6-hsa-miR-429- CHRDL1/CCNA2 Axis for Lung Adenocarcinoma Prognosis Evaluation


Citar

Texto integral

Resumo

Aims:To explore an exosome-relevant molecular classification in lung adenocarcinoma (LUAD).

Background:Exosome genes or relevant non-coding RNAs are regulators of cancer treatment and prognosis, but their function in LUAD has not yet been determined.

Objective:Unraveling a molecular classification applying exosome-related RNA networks for LUAD prognosis evaluation.

Methods:MicroRNA sequencing data (miRNAs-seq) and RNA sequencing data (RNA- seq) were derived from The Cancer Genome Atlas (TCGA). The ConsensusCluster- Plus package was used for molecular typing in LUAD based on 121 Exosome-related genes. Then, a limma package was conducted to explore differentially expressed mRNAs (DEmRNAs), differentially expressed miRNAs (DEmiRNAs) and differentially expressed lncRNAs (DElncRNAs) in molecular typing for constructing an Exosome-driven competing endogenous RNA network (ceRNA). Dominant miRNAs, as well as target mRNAs, were identified by COX modeling and Kaplan-Meier survival analysis.

Results:Two Exosome-associated molecular clusters classified in LUAD. The C2 cluster favored high clinicopathology and showed a trend toward poor prognosis. 29 lncRNA- miRNA and 12 miRNA-mRNA interaction pairs were identified. The hsa-miR-429 was the pivotal miRNA in the network that affected the prognosis of LUAD. According to the interaction relationship and LUAD prognostic role, SNHG6-hsa- miR-429-CHRDL1/CCNA2 was identified. SNHG6-hsa-miR-429-CHRDL1 exerts oncogenic effects, and SNHG6-hsa-miR-429- CCNA2 exerts pro-oncogenic effects.

Conclusion:Overall, our study identified an Exosome-driven ceRNA network in LUAD, and the SNHG6-hsa-miR-429-CHRDL1/CCNA2 axis could be a new therapeutic target for LUAD and our study provides new insights into the molecular mechanisms of LUAD.

Sobre autores

Yuan Yuan

Department of Respiration, Nanjing First Hospital

Email: info@benthamscience.net

Qian Li

Department of Respiration, Nanjing First Hospital

Email: info@benthamscience.net

Feifei Chen

Department of Respiration, Nanjing First Hospital

Email: info@benthamscience.net

Yujie Zhao

Shenzhen Engineering Center for Translational Medicine of Precision Cancer Immunodiagnosis and Therapy, YuceBio Technology Co., Ltd, Regional marketing department

Email: info@benthamscience.net

Jiyong Ma

Department of Respiration, Nanjing First Hospital

Autor responsável pela correspondência
Email: info@benthamscience.net

Surong Fang

Department of Respiration, Nanjing First Hospital

Autor responsável pela correspondência
Email: info@benthamscience.net

Bibliografia

  1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249. doi: 10.3322/caac.21660 PMID: 33538338
  2. Herbst, R.S.; Morgensztern, D.; Boshoff, C. The biology and management of non-small cell lung cancer. Nature, 2018, 553(7689), 446-454. doi: 10.1038/nature25183 PMID: 29364287
  3. Chen, D.; Wang, R.; Yu, C.; Cao, F.; Zhang, X.; Yan, F.; Chen, L.; Zhu, H.; Yu, Z.; Feng, J. FOX-A1 contributes to acquisition of chemoresistance in human lung adenocarcinoma via transactivation of SOX5. EBioMedicine, 2019, 44, 150-161. doi: 10.1016/j.ebiom.2019.05.046 PMID: 31147293
  4. Xu, L.; Li, K.; Li, J.; Liu, L.; Xu, F.; Xu, Y.; Kong, Y.; Pu, X.; Wang, Q.; Wang, J.; Chen, B.; Wu, L. MiR-21/sonic hedgehog (SHH)/PI3K/AKT pathway is associated with NSCLC of primary EGFR-TKI resistance. Oncologie, 2022, 24(3), 579-590. doi: 10.32604/oncologie.2022.022121
  5. Song, Y.; Yan, S.; Fan, W.; Zhang, M.; Liu, W.; Lu, H.; Cao, M.; Hao, C.; Chen, L.; Tian, F.; Zhan, Y.; Cai, L.; Xing, Y. Identification and validation of the immune subtypes of lung adenocarcinoma: Implications for immunotherapy. Front. Cell Dev. Biol., 2020, 8, 550. doi: 10.3389/fcell.2020.00550 PMID: 32719796
  6. Zhang, L.; Yu, D. Exosomes in cancer development, metastasis, and immunity. Biochim. Biophys. Acta Rev. Cancer, 2019, 1871(2), 455-468. doi: 10.1016/j.bbcan.2019.04.004 PMID: 31047959
  7. Zhang, H.; Wang, X.; Yu, Y.; Yang, Z. Progression of exosome-mediated chemotherapy resistance in cancer. Oncologie, 2022, 24(2), 247-259. doi: 10.32604/oncologie.2022.020993
  8. Kalluri, R.; LeBleu, V.S. The biology, function, and biomedical applications of exosomes. Science, 2020, 367(6478), eaau6977. doi: 10.1126/science.aau6977 PMID: 32029601
  9. Li, M.Y.; Liu, L.Z.; Dong, M. Progress on pivotal role and application of exosome in lung cancer carcinogenesis, diagnosis, therapy and prognosis. Mol. Cancer, 2021, 20(1), 22. doi: 10.1186/s12943-021-01312-y PMID: 33504342
  10. Zhang, K.; Chen, J.; Li, C.; Yuan, Y.; Fang, S.; Liu, W.; Qian, Y.; Ma, J.; Chang, L.; Chen, F.; Yang, Z.; Gu, W. Exosome-mediated transfer of SNHG7 enhances docetaxel resistance in lung adenocarcinoma. Cancer Lett., 2022, 526, 142-154. doi: 10.1016/j.canlet.2021.10.029 PMID: 34715254
  11. Yu, Z.; Tang, H.; Chen, S.; Xie, Y.; Shi, L.; Xia, S.; Jiang, M.; Li, J.; Chen, D. Exosomal LOC85009 inhibits docetaxel resistance in lung adenocarcinoma through regulating ATG5-induced autophagy. Drug Resist. Updat., 2023, 67, 100915. doi: 10.1016/j.drup.2022.100915 PMID: 36641841
  12. Zhang, W.; Bai, M.; Liu, K.; Tan, J.; Ma, J.; Zhao, J.; Hou, P. LncRNA surfactant associated 1 activates large tumor suppressor kinase 1/Yes-associated protein pathway via modulating hypoxic exosome-delivered miR-4766–5p to inhibit lung adenocarcinoma metastasis. Int. J. Biochem. Cell Biol., 2022, 153, 106317. doi: 10.1016/j.biocel.2022.106317 PMID: 36283586
  13. Chan, J.; Tay, Y. Noncoding RNA:RNA regulatory networks in cancer. Int. J. Mol. Sci., 2018, 19(5), 1310. doi: 10.3390/ijms19051310 PMID: 29702599
  14. Wang, L.; Cho, K.B.; Li, Y.; Tao, G.; Xie, Z.; Guo, B. Long noncoding RNA (lncRNA)-mediated competing endogenous RNA networks provide novel potential biomarkers and therapeutic targets for colorectal cancer. Int. J. Mol. Sci., 2019, 20(22), 5758. doi: 10.3390/ijms20225758 PMID: 31744051
  15. Shuwen, H.; Qing, Z.; Yan, Z.; Xi, Y. Competitive endogenous RNA in colorectal cancer: A systematic review. Gene, 2018, 645, 157-162. doi: 10.1016/j.gene.2017.12.036 PMID: 29273554
  16. Li, Y.; Yu, X.; Zhang, Y.; Wang, X.; Zhao, L.; Liu, D.; Zhao, G.; Gao, X.; Fu, J.; Zang, A.; Jia, Y. Identification of a novel prognosis-associated ceRNA network in lung adenocarcinoma via bioinformatics analysis. Biomed. Eng. Online, 2021, 20(1), 117. doi: 10.1186/s12938-021-00952-x PMID: 34819106
  17. Wu, X.; Sui, Z.; Zhang, H.; Wang, Y.; Yu, Z. Integrated analysis of lncRNA–Mediated ceRNA network in lung adenocarcinoma. Front. Oncol., 2020, 10, 554759. doi: 10.3389/fonc.2020.554759 PMID: 33042838
  18. Shen, W.; Song, Z.; Zhong, X.; Huang, M.; Shen, D.; Gao, P.; Qian, X.; Wang, M.; He, X.; Wang, T.; Li, S.; Song, X. Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform. iMeta, 2022, 1(3), e36. doi: 10.1002/imt2.36
  19. Wilkerson, M.D.; Hayes, D.N. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics, 2010, 26(12), 1572-1573. doi: 10.1093/bioinformatics/btq170 PMID: 20427518
  20. Shah, S.N.A.; Parveen, R. An extensive review on lung cancer diagnosis using machine learning techniques on radiological data: State-of-the-art and perspectives. Arch. Comput. Methods Eng., 2023, 30(8), 4917-4930. doi: 10.1007/s11831-023-09964-3
  21. Ritchie, M.E.; Phipson, B.; Wu, D.; Hu, Y.; Law, C.W.; Shi, W.; Smyth, G.K. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res., 2015, 43(7), e47. doi: 10.1093/nar/gkv007 PMID: 25605792
  22. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res., 2003, 13(11), 2498-2504. doi: 10.1101/gr.1239303 PMID: 14597658
  23. Yu, G.; Wang, L.G.; Han, Y.; He, Q.Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS, 2012, 16(5), 284-287. doi: 10.1089/omi.2011.0118 PMID: 22455463
  24. Therneau, T.M.; Lumley, T. Package ‘survival’. R Top Doc, 2015, 128(10), 28-33.
  25. Simon, N.; Friedman, J.; Hastie, T.; Tibshirani, R. Regularization paths for Cox’s proportional hazards model via coordinate descent. J. Stat. Softw., 2011, 39(5), 1-13. doi: 10.18637/jss.v039.i05 PMID: 27065756
  26. Ripley, B. Package ‘mass’. Cran r, 2013, 538, 113-120.
  27. Li, T.; Fan, J.; Wang, B.; Traugh, N.; Chen, Q.; Liu, J.S.; Li, B.; Liu, X.S. TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res., 2017, 77(21), e108-e110. doi: 10.1158/0008-5472.CAN-17-0307 PMID: 29092952
  28. Ru, B.; Wong, C.N.; Tong, Y.; Zhong, J.Y.; Zhong, S.S.W.; Wu, W.C.; Chu, K.C.; Wong, C.Y.; Lau, C.Y.; Chen, I.; Chan, N.W.; Zhang, J. TISIDB: an integrated repository portal for tumor–immune system interactions. Bioinformatics, 2019, 35(20), 4200-4202. doi: 10.1093/bioinformatics/btz210 PMID: 30903160
  29. Aryee, M.J.; Jaffe, A.E.; Corrada-Bravo, H.; Ladd-Acosta, C.; Feinberg, A.P.; Hansen, K.D.; Irizarry, R.A. Minfi: a flexible and comprehensive bioconductor package for the analysis of infinium DNA methylation microarrays. Bioinformatics, 2014, 30(10), 1363-1369. doi: 10.1093/bioinformatics/btu049 PMID: 24478339
  30. Chen, Y.; Wu, H.; Jiao, A.; Tong, J.; Zhu, J.; Zhang, M.; Li, Z.; Li, P. Chinese herbal prescription QYSL prevents progression of lung cancer by targeting tumor microenvironment. Oncologie, 2022, 24(2), 295-307. doi: 10.32604/oncologie.2022.022116
  31. Lang, Y.; Xu, S.; Ma, J.; Wu, J.; Jin, S.; Cao, S.; Yu, Y. MicroRNA-429 induces tumorigenesis of human non-small cell lung cancer cells and targets multiple tumor suppressor genes. Biochem. Biophys. Res. Commun., 2014, 450(1), 154-159. doi: 10.1016/j.bbrc.2014.05.084 PMID: 24866238
  32. Wang, J.; Lai, X.; Peng, X. CircLIFR inhibits non-small cell lung cancer progression by acting as a miR-429 sponge to enhance CELF2 expression. Biochem. Genet., 2023, 61(2), 725-741. doi: 10.1007/s10528-022-10285-6 PMID: 36104590
  33. Zhang, C.W.; Zhou, B.; Liu, Y.C.; Su, L.W.; Meng, J.; Li, S.L.; Wang, X.L. LINC00365 inhibited lung adenocarcinoma progression and glycolysis via sponging MIR -429/KCTD12 axis. Environ. Toxicol., 2022, 37(8), 1853-1866. doi: 10.1002/tox.23532 PMID: 35426242
  34. Liang, R.; Xiao, G.; Wang, M.; Li, X.; Li, Y.; Hui, Z.; Sun, X.; Qin, S.; Zhang, B.; Du, N.; Liu, D.; Ren, H. SNHG6 functions as a competing endogenous RNA to regulate E2F7 expression by sponging miR-26a-5p in lung adenocarcinoma. Biomed. Pharmacother., 2018, 107, 1434-1446. doi: 10.1016/j.biopha.2018.08.099 PMID: 30257360
  35. Chen, C.; Guo, Q.; Song, Y.; Xu, G.; Liu, L. SKA1/2/3 serves as a biomarker for poor prognosis in human lung adenocarcinoma. Transl. Lung Cancer Res., 2020, 9(2), 218-231. doi: 10.21037/tlcr.2020.01.20 PMID: 32420061
  36. Li, Z.; Zhang, Y.; Zhou, Y.; Wang, F.; Yin, C.; Ding, L.; Zhang, S. Tanshinone IIA suppresses the progression of lung adenocarcinoma through regulating CCNA2-CDK2 complex and AURKA/PLK1 pathway. Sci. Rep., 2021, 11(1), 23681. doi: 10.1038/s41598-021-03166-2 PMID: 34880385
  37. Deng, B.; Chen, X.; Xu, L.; Zheng, L.; Zhu, X.; Shi, J.; Yang, L.; Wang, D.; Jiang, D. Chordin-like 1 is a novel prognostic biomarker and correlative with immune cell infiltration in lung adenocarcinoma. Aging (Albany NY), 2022, 14(1), 389-409. doi: 10.18632/aging.203814 PMID: 35021154
  38. Ahmad, S.; Raza, K. Identification of 5-nitroindazole as a multitargeted inhibitor for CDK and transferase kinase in lung cancer: a multisampling algorithm-based structural study. Mol. Divers., 2023. doi: 10.1007/s11030-023-10648-0 PMID: 37058176
  39. Ahmad, S.; Singh, V.; Gautam, H.K.; Raza, K. Multisampling-based docking reveals Imidazolidinyl urea as a multitargeted inhibitor for lung cancer: an optimisation followed multi-simulation and in-vitro study. J. Biomol. Struct. Dyn., 2023, 1-18. doi: 10.1080/07391102.2023.2209673 PMID: 37154501

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bentham Science Publishers, 2024